Luca Potestio (L Potestio)

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 196

Top Venues

Clinical, cosmetic and investigational dermatology

Clinical and experimental dermatology

Expert opinion on drug safety

Journal of the European Academy of Dermatology and Venereology : JEADV

This page only lists publications with an associated author ORCID identifier.

Publications

Fabrizio Martora, Claudio Marasca, Sara Cacciapuoti, Federica Fariello, Luca Potestio, Teresa Battista, Massimiliano Scalvenzi, Matteo Megna
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study. Clinical, cosmetic and investigational dermatology 17 (2024)
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert opinion on pharmacotherapy (2024)
Francesco Caso, Mauro Fatica, Mario Ferraioli, Matteo Megna, Luca Potestio, Angelo Ruggiero, Nello Tommasino, Francesco Maione, Raffaele Scarpa, Maria Sole Chimenti, Luisa Costa
The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis. Expert opinion on biological therapy (2024)
Diego Orsini, Chiara Assorgi, Claudio Bonifati, Norma Cameli, Dario Graceffa, Luca Potestio, Matteo Megna
Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study). The Journal of dermatological treatment 35 (1) (2024)
Fabrizio Martora, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Fabrizio Martora, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Luca Potestio, Cataldo Patruno, Stefano Dastoli, Claudio Brescia, Maddalena Napolitano
Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations. Journal of asthma and allergy 17 (2024)
Fabrizio Martora, Teresa Battista, Luca Potestio, Antonio Portarapillo, Nello Tommasino, Matteo Megna
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Matteo Megna, Ruggiero Angelo, Nello Tommasino, Claudio Brescia, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Massimiliano Scalvenzi, Aimillios Lallas, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Laura Marano, Alessia Villani
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation. Cancers 16 (9) (2024)
Sara Cacciapuoti, Luca Potestio, Gallo Lucia, Musumeci Maria Letizia, Giacomo Caldarola, Domenico D'Amico, Caudullo Francesco, Papaianni Valeria, Clara De Simone, Ketty Peris, Matteo Megna
Short-term efficacy of tildrakizumab on difficult-to-treat areas: a real-world experience. International journal of dermatology (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero, Matteo Megna
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert opinion on drug safety (2024)
Francesco Caso, Mauro Fatica, Mario Ferraioli, Matteo Megna, Luca Potestio, Angelo Ruggiero, Nello Tommasino, Francesco Maione, Raffaele Scarpa, Maria Sole Chimenti, Luisa Costa
The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis. Expert opinion on biological therapy (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Fabrizio Martora, Matteo Megna
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities. Dermatology and therapy 14 (4) (2024)
Matteo Megna, Ruggiero Angelo, Fabrizio Martora, Ylenia Vallone, Gianluca Guerrasio, Luca Potestio
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. Journal of clinical medicine 13 (9) (2024)
Diego Orsini, Chiara Assorgi, Claudio Bonifati, Norma Cameli, Dario Graceffa, Luca Potestio, Matteo Megna
Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study). The Journal of dermatological treatment 35 (1) (2024)
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert opinion on pharmacotherapy 25 (9) (2024)
Alessia Villani, Luca Potestio, Aimilios Lallas, Zoe Apalla, Massimiliano Scalvenzi, Fabrizio Martora
Unaddressed Challenges in the Treatment of Cutaneous Melanoma? Medicina (Kaunas, Lithuania) 60 (6) (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero, Matteo Megna
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert opinion on drug safety (2024)
Fabrizio Martora, Matteo Megna, Teresa Battista, Massimiliano Scalvenzi, Alessia Villani, Sara Cacciapuoti, Luca Potestio
Viral reactivation following COVID-19 vaccination: a review of the current literature. Clinical and experimental dermatology 49 (6) (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Matteo Megna, Sara Cacciapuoti, Fabrizio Martora, Alessia Villani
Author Reply to "Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?" by Duff et al. Clinical and experimental dermatology (2024)
Nello Tommasino, Matteo Megna, Sara Cacciapuoti, Alessia Villani, Fabrizio Martora, Ruggiero Angelo, Lucia Genco, Luca Potestio
The Past, the Present and the Future of Teledermatology: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Fabrizio Martora, Matteo Megna
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities. Dermatology and therapy 14 (4) (2024)
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert opinion on pharmacotherapy 25 (9) (2024)
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, Ylenia Vallone, Teresa Battista, Matteo Megna
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, Ylenia Vallone, Teresa Battista, Matteo Megna
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials. Clinical, cosmetic and investigational dermatology 17 (2024)
Fabrizio Martora, Claudio Marasca, Sara Cacciapuoti, Federica Fariello, Luca Potestio, Teresa Battista, Massimiliano Scalvenzi, Matteo Megna
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Fabrizio Martora, Matteo Megna
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities. Dermatology and therapy 14 (4) (2024)
Fabrizio Martora, Maria Carmela Annunziata, Luca Potestio, Teresa Battista, Ruggiero Angelo, Matteo Megna
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report. Clinical, cosmetic and investigational dermatology 17 (2024)
Teresa Battista, Vincenzo Picone, Matteo Noto, Luca Potestio, Angelo Ruggiero, Fabrizio Martora, Matteo Megna, Lucia Genco
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis. Expert opinion on drug safety (2024)
Fabrizio Martora, Teresa Battista, Luca Potestio, Antonio Portarapillo, Nello Tommasino, Matteo Megna
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report. Clinical, cosmetic and investigational dermatology 17 (2024)
Teresa Battista, Vincenzo Picone, Matteo Noto, Luca Potestio, Angelo Ruggiero, Fabrizio Martora, Matteo Megna, Lucia Genco
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis. Expert opinion on drug safety (2024)
Matteo Megna, Ruggiero Angelo, Fabrizio Martora, Ylenia Vallone, Gianluca Guerrasio, Luca Potestio
Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. Journal of clinical medicine 13 (9) (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero, Matteo Megna
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert opinion on drug safety 23 (6) (2024)
Alessia Villani, Luca Potestio, Aimilios Lallas, Zoe Apalla, Massimiliano Scalvenzi, Fabrizio Martora
Unaddressed Challenges in the Treatment of Cutaneous Melanoma? Medicina (Kaunas, Lithuania) 60 (6) (2024)
Teresa Battista, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi, Matteo Megna
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of clinical medicine 13 (7) (2024)
Fabrizio Martora, Luca Potestio, Teresa Battista, Matteo Megna
Reply to "Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa". Journal of the European Academy of Dermatology and Venereology : JEADV 38 (8) (2024)
Matteo Megna, Ruggiero Angelo, Ginevra Torta, Fabrizio Martora, Mariateresa Bianco, Luca Potestio
Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced. Clinical and experimental dermatology (2024)
Luca Potestio, Massimiliano Scalvenzi, Aimillios Lallas, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Laura Marano, Alessia Villani
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation. Cancers 16 (9) (2024)
Matteo Megna, Ruggiero Angelo, Nello Tommasino, Claudio Brescia, Fabrizio Martora, Sara Cacciapuoti, Luca Potestio
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Fabrizio Martora, Matteo Megna
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities. Dermatology and therapy (2024)
Cataldo Patruno, Luca Potestio, Daniele Cecere, Andrea Cosenza, Claudio Brescia, Maddalena Napolitano
The impact of body mass index on dupilumab treatment outcomes in adult atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Matteo Megna, Giuseppe Lauletta, Nello Tommasino, Antonia Salsano, Teresa Battista, Angelo Ruggiero, Fabrizio Martora, Luca Potestio
Management of Psoriasis Patients with Serious Infectious Diseases. Advances in therapy 41 (6) (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Fabrizio Martora, Matteo Megna
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities. Dermatology and therapy 14 (4) (2024)
Antonio Portarapillo, Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Antonia Salsano, Fabrizio Martora, Francesco Caso, Matteo Megna
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond. Expert opinion on pharmacotherapy (2024)
Luca Potestio, Giuseppe Lauletta, Nello Tommasino, Antonio Portarapillo, Antonia Salsano, Teresa Battista, Fabrizio Martora, Matteo Megna
Risk Factors for Psoriasis Flares: A Narrative Review. Psoriasis (Auckland, N.Z.) 14 (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Antonia Salsano, Gioacchino Lucagnano, Luca Menna, Gianluca Esposito, Fabrizio Martora, Matteo Megna
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review. Advances in therapy (2024)
Teresa Battista, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi, Matteo Megna
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of clinical medicine 13 (7) (2024)
Luca Potestio, Cataldo Patruno, Diego Colonna, Gioacchino Lucagnano, Annalisa Passariello, Pasqualina Ruggiero, Maria Giovanna Russo, Maddalena Napolitano
A case of allergic contact dermatitis due to implantable cardioverter-defibrillator. Contact dermatitis (2024)
Matteo Megna, Giuseppe Lauletta, Nello Tommasino, Antonia Salsano, Teresa Battista, Angelo Ruggiero, Fabrizio Martora, Luca Potestio
Management of Psoriasis Patients with Serious Infectious Diseases. Advances in therapy 41 (6) (2024)
Matteo Megna, Giuseppe Lauletta, Nello Tommasino, Antonia Salsano, Teresa Battista, Angelo Ruggiero, Fabrizio Martora, Luca Potestio
Management of Psoriasis Patients with Serious Infectious Diseases. Advances in therapy (2024)
Luca Potestio, Matteo Megna, Sara Cacciapuoti, Fabrizio Martora, Alessia Villani
Author Reply to "Comment on ChatGPT and Medical Writing in Dermatology: why should we keep writing?" by Daungsupawong et al. Clinical and experimental dermatology (2024)
D Orsini, M Megna, C Assorgi, A Balato, R Balestri, N Bernardini, A Bettacchi, Tommaso Bianchelli, L Bianchi, G Buggiani, Martina Burlando, Amg Brunasso, G Caldarola, N Cameli, A Campanati, E Campione, A Carugno, K Chersi, A Conti, A Costanzo, E Cozzani, A Cuccia, D D'Amico, G Dal Bello, E G Dall'Olio, P Dapavo, C De Simone, E V Di Brizzi, A Di Cesare, V Dini, M Esposito, E Errichetti, M C Fargnoli, C S Fiorella, A Foti, Z Fratton, F M Gaiani, P Gisondi, R Giuffrida, A Giunta, C Guarneri, A Legori, F Loconsole, P Malagoli, A Narcisi, M Paolinelli, Luca Potestio, F Prignano, G Rech, A Rossi, N Skroza, F Trovato, M Venturini, A G Richetta, G Pellacani, A Dattola
Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study - IL PSO (Italian Landscape Psoriasis). The Journal of dermatological treatment 35 (1) (2024)
Luca Potestio, Michela D'Agostino, Antonio Portarapillo, Valeria Esposito, Nello Tommasino, Antonia Salsano, Luigi Guerriero, Fabrizio Martora, Matteo Megna
Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris. Life (Basel, Switzerland) 14 (8) (2024)
Antonio Portarapillo, Valeria Esposito, Matteo Megna, Luca Potestio, Rosita Comune, Fabrizio Martora, Ruggiero Angelo
The role of teledermatology for the long-term management of stable psoriasis treated with biologics: a survey-based study. Clinical and experimental dermatology (2024)
Francesco Caso, Mauro Fatica, Mario Ferraioli, Matteo Megna, Luca Potestio, Angelo Ruggiero, Nello Tommasino, Francesco Maione, Raffaele Scarpa, Maria Sole Chimenti, Luisa Costa
The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis. Expert opinion on biological therapy 24 (8) (2024)
Teresa Battista, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi, Matteo Megna
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of clinical medicine 13 (7) (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Matteo Megna, Sara Cacciapuoti, Fabrizio Martora, Alessia Villani
ChatGPT and Medical Writing in Dermatology: why should we keep writing? Clinical and experimental dermatology (2024)
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Federica Feo, Angelo Ruggiero, Fabrizio Martora, Antonio Portarapillo, Luigi Guerriero, Matteo Megna
Efficacy and safety of deucravacitinib for the management of psoriasis: a drug safety evaluation. Expert opinion on drug safety 23 (6) (2024)
Matteo Megna, Giuseppe Lauletta, Nello Tommasino, Antonia Salsano, Teresa Battista, Angelo Ruggiero, Fabrizio Martora, Luca Potestio
Management of Psoriasis Patients with Serious Infectious Diseases. Advances in therapy 41 (6) (2024)
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, Ylenia Vallone, Teresa Battista, Matteo Megna
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials. Clinical, cosmetic and investigational dermatology 17 (2024)
Nello Tommasino, Matteo Megna, Sara Cacciapuoti, Alessia Villani, Fabrizio Martora, Ruggiero Angelo, Lucia Genco, Luca Potestio
The Past, the Present and the Future of Teledermatology: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Cataldo Patruno, Maddalena Napolitano
Comment on 'Dupilumab for atopic dermatitis in metastatic cancer'. The Australasian journal of dermatology (2024)
Luca Potestio, Matteo Megna, Sara Cacciapuoti, Fabrizio Martora, Alessia Villani
ChatGPT and medical writing in dermatology: why should we keep writing? Clinical and experimental dermatology 49 (8) (2024)
Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Maria Letizia Musumeci, Giacomo Caldarola, Domenico D'Amico, Francesco Caudullo, Valeria Papaianni, Clara De Simone, Ketty Peris, Matteo Megna
Short-term efficacy of tildrakizumab on difficult-to-treat areas: a real-world experience. International journal of dermatology (2024)
Fabrizio Martora, Matteo Megna, Teresa Battista, Massimiliano Scalvenzi, Alessia Villani, Sara Cacciapuoti, Luca Potestio
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature. Clinical and experimental dermatology (2024)
Fabrizio Martora, Maria Carmela Annunziata, Luca Potestio, Teresa Battista, Ruggiero Angelo, Matteo Megna
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration - A Case Report. Clinical, cosmetic and investigational dermatology 17 (2024)
Luca Potestio, Fabrizio Martora, Sara Cacciapuoti, Matteo Megna, Alessia Villani, Ruggiero Angelo
Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review. Clinical, cosmetic and investigational dermatology 17 (2024)
Michela D'Agostino, Fabrizio Martora, Matteo Megna, Maddalena Napolitano, Luca Potestio
Lichen planus following Covid-19 vaccination: a narrative review. Clinical and experimental dermatology (2024)
Luca Potestio, Cataldo Patruno, Stefano Dastoli, Claudio Brescia, Maddalena Napolitano
Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations. Journal of asthma and allergy 17 (2024)
Luca Potestio, Giuseppe Lauletta, Nello Tommasino, Antonio Portarapillo, Antonia Salsano, Teresa Battista, Fabrizio Martora, Matteo Megna
Risk Factors for Psoriasis Flares: A Narrative Review. Psoriasis (Auckland, N.Z.) 14 (2024)
Luca Potestio, Fabrizio Martora, Alessia Villani, Ruggiero Angelo, Massimiliano Scalvenzi, Matteo Megna
ChatGPT and Dermatology: friends or foes? Clinical and experimental dermatology (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Teresa Battista, Luigi Fornaro, Luca Potestio, Ruggiero Angelo, Matteo Megna
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data. Clinical, cosmetic and investigational dermatology 16 (2023)
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Ruggiero Angelo, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of clinical medicine 12 (8) (2023)
Luca Potestio, Fabrizio Martora, Alessia Villani, Sara Cacciapuoti, Teresa Battista, Matteo Megna
Advancing Dermatology: Embracing the Power of Artificial Intelligence. Clinical and experimental dermatology (2023)
Luca Potestio, Fabrizio Martora, Matteo Megna, Alessia Villani, Sara Cacciapuoti
Comment on 'Development of Chilblains Lesions During the COVID-19 Pandemic is Strongly Associated with Cold Weather: Retrospective Analysis of Patients from a Single Center in the United States'. Clinical and experimental dermatology (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Luca Potestio, Angelo Ruggiero, Gabriella Fabbrocini, Fabrizio Martora, Matteo Megna
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature. Psoriasis (Auckland, N.Z.) 13 (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert opinion on drug safety 22 (1) (2023)
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, Matteo Megna, Luca Potestio, Luigi Fornaro, Melania Parisi, Maria Antonietta Luciano, Ruggiero Angelo, Anna Testa, Fabiana Castiglione, Cataldo Patruno, Maria Quaranta, Gabriella Fabbrocini
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders. Journal of clinical medicine 12 (8) (2023)
Ruggiero Angelo, Luca Potestio, Fabrizio Martora, Alessia Villani, Rosita Comune, Matteo Megna
Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert opinion on drug safety (2023)
Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna, Massimiliano Scalvenzi, Teresa Battista, Alessia Villani, Luca Potestio
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? Life (Basel, Switzerland) 13 (4) (2023)
Fabrizio Martora, Gabriella Fabbrocini, Matteo Megna, Massimiliano Scalvenzi, Teresa Battista, Alessia Villani, Luca Potestio
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? Life (Basel, Switzerland) 13 (4) (2023)
Luca Potestio, Alessia Villani, Flavia Raia, Gabriella Fabbrocini, Fabrizio Martora
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256". Journal of cosmetic dermatology 22 (3) (2023)
Sara Cacciapuoti, Matteo Megna, Emanuela Salza, Luca Potestio, Giuseppina Caiazzo
The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study. The Journal of dermatological treatment 35 (1) (2023)
Luca Potestio, Massimiliano Scalvenzi, Fabrizio Martora, Luca Costanzo, Lucia Gallo
Comment on "Permethrin-unresponsive scabies in London, United Kingdom - a wake up call". Clinical and experimental dermatology (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Fabrizio Martora, Massimiliano Scalvenzi, Ruggiero Angelo, Luca Potestio, Teresa Battista, Matteo Megna
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas, Lithuania) 59 (4) (2023)
Luca Potestio, Fabrizio Martora, Alessia Villani, Matteo Megna, Ruggiero Angelo
Comment on: "Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination" by Gambichler. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Matteo Megna, Ruggiero Angelo, Antonia Salsano, Giuseppe Lauletta, Antonio Portarapillo, Ginevra Torta, Fabrizio Martora, Luca Potestio
A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab. Clinical, cosmetic and investigational dermatology 16 (2023)
Fabrizio Martora, Teresa Battista, Gabriella Fabbrocini, Luca Potestio
Comment on 'Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination'. Clinical and experimental dermatology 48 (1) (2023)
Luca Potestio, Alessia Villani, Flavia Raia, Gabriella Fabbrocini, Fabrizio Martora
Letter to the editor regarding article "Falotico JM, Gu L, Lipner SR. Not just pimple popping: The utility of hybrid telemedicine models beyond acne management amidst the ongoing COVID-19 pandemic. J Cosmet Dermatol. 2022;10.1111/jocd.15256". Journal of cosmetic dermatology 22 (3) (2023)
Matteo Megna, Elisa Camela, Teresa Battista, Lucia Genco, Fabrizio Martora, Matteo Noto, Vincenzo Picone, Ruggiero Angelo, Giuseppe Monfrecola, Gabriella Fabbrocini, Luca Potestio
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert opinion on drug safety (2023)
Matteo Megna, Luca Potestio, Ruggiero Angelo, Sara Cacciapuoti, Francesco Maione, Marco Tasso, Francesco Caso, Luisa Costa
JAK Inhibitors in Psoriatic Disease. Clinical, cosmetic and investigational dermatology 16 (2023)
Luca Potestio, Matteo Megna, Alessia Villani, Sara Cacciapuoti, Massimiliano Scalvenzi, Fabrizio Martora
Herpes Zoster and COVID-19 Vaccination: A Narrative Review. Clinical, cosmetic and investigational dermatology 16 (2023)
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, Sabatino Pallotta, Matteo Megna
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert opinion on investigational drugs (2023)
Ruggiero Angelo, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Matteo Megna
Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study. Clinical, cosmetic and investigational dermatology 16 (2023)

Luca Potestio.css-eqlu8i{font-size:small;padding-left:4px;} (L Potestio)

Publication Activity (10 Years)

Top Topics

Top Venues

Luca Potestio (L Potestio)